Topical corticosteroids in dermatology

Journal of Drugs in Dermatology

Volumn 8, Issue 12, 2009, Pages 1093-1105

  Tadicherla, Sujatha ^a   Ross, Kate ^a   Shenefelt, Philip D ^a   Fenske, Neil A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCLOMETASONE DIPROPIONATE; AMCINONIDE; APEXICON E; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CLOBETASOL PROPIONATE; CLOCORTOLONE PIVALATE; CORTICOSTEROID; DESONIDE; DESOXIMETASONE; DIFLORASONE DIACETATE; FLUDROXYCORTIDE; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; FLUTICASONE PROPIONATE; HALCINONIDE; HALOG E; HYDROCORTISONE; HYDROCORTISONE 17 BUTYRATE 21 PROPIONATE; HYDROCORTISONE ACETATE; HYDROCORTISONE BUTYRATE; HYDROCORTISONE VALERATE; LOKARA; MICORT HC; MOMETASONE FUROATE; OLUX 68; OLUX E 69; PREDNICARBATE; TRIAMCINOLONE; TRIAMCINOLONE ACETATE; TRIAMCINOLONE ACETONIDE; ULOBETASOL PROPIONATE; UNCLASSIFIED DRUG; DRUG VEHICLE;

ACNE; AEROSOL; ARTICLE; ATROPHY; CHLORINATION; CONTACT SENSITIZATION; CORTICOSTEROID THERAPY; CREAM; CROSS REACTION; CUSHING SYNDROME; DERMATITIS; DERMATOLOGY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG POTENCY; FEMUR HEAD NECROSIS; FLUORINATION; GEL; GROWTH RETARDATION; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPERTRICHOSIS; HYPOPIGMENTATION; LOTION; OINTMENT; PURPURA; ROSACEA; STRIA; TELANGIECTASIA; TREATMENT DURATION; CONTACT DERMATITIS; REVIEW; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION; VEHICLES;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; CROSS REACTIONS; DERMATITIS, CONTACT; HUMANS; SKIN DISEASES; VEHICLES;

EID: 74049093153     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (148)

1. Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol. 1952;19(2):101-102.
2. Stem R. The pattern of topical corticosteroid prescribing in the United States, 1989-1991. J Am Acad Dermatol. 1996:183-196.
3. Giannotti B, Pimpinelli N. Topical corticosteroids: Which drug and when? Drugs 1992;44(1):65-71.
4. Baumann L, Kerdel F. Topical glucocorticoids. In: Fitzpatrick T, ed. Dermatology in General Medicine. 5th ed. New York. McGraw Hill, 1999:2713-2717.
5. McKenzie AW, Stoughton RB: Method for comparing percutaneous absorption of steroids. 1962;86:608-610.
6. Cornell RC, Stoughton RB. Correlation of the vasoconstrictive assay and clinical activity in psoriasis. Arch Dermatol. 1985:121:63-67 (Pubitemid 16225021)
7. Goa KL. Clinical pharmacology and pharmacokinetic properties of topically applied corticosteroids - A review. Drugs. 1988;36(Suppl 5);51-61.
8. Wang RIH, Sytkowski A, Shetty KR. Relating corticosteroid structure and function. Drug Therapy. 1975;143-148.
9. Shroot B, Pillai R. Potency and side effects of halogenated corticosteroids revisited. Poster presentation (P-416). American Academy of Dermatology. 2005.
10. Hughes J, Rustin M. Corticosteroids. Clin Dermatol. 1997;15(5):715-721. (Pubitemid 27411305)
11. Stoughton RB. Vasoconstrictor assay - Specific applications. In: Maibach HI, Surber C editor. Topical Corticosteroids. New York: Karger; 1992:42-53.
12. Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol. 1989;125(10):1509-1514.
13. Franz T. Pharmacokinetics and the skin in dermatology. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. Mosby, London. 2003:1975-1978.
14. Vicker CFH (1963) Existence of a reservoir in the stratum corneum. Arch Dermatol. 1963;88:20-23.
15. Lee NP, Arriola ER. Topical corticosteroids: Back to basics. West J Med. 1999; 171(5-6):351-353.
16. Sheman. AJ. Proper use of topical corticosteroids. In: Frankel DH. Field Guide to Clinical Dermatology. 2nd ed. New Jersey: LWW, 2006:3.
17. Maibach HI. Invivo percutaneous penetration of corticosteroids in man and unresolved problems in the efficacy. Dermatologica. 1976;152 Suppl 1:11-25.
18. Huang X, Tanojo H, Lenn J, et al. A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol. 2005;53(1 Suppl 1):S26-S38. (Pubitemid 40828179)
19. Drake L, Dinehart S, Farmer E, et al. Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol. 1996;35(4):615-619. (Pubitemid 26427069)
20. Yohn JJ, Weston WL. Topical glucocorticosteroids. Curr Probl Dermatol. 1990;2:38-63.
21. Feldman RJ, Maibach HI. Regional variation in percutaneous penetration of 14 C cortisol in man. J Invest Dermatol. 1967;48:181-183.
22. Turpeinen M, Salo OP, Leisti S. Effect of percutaneous absorption of hydrocortisone on adrenocortical responsiveness in infants with severe skin disease. Br J Dermatol. 1986;115(4):475-484. (Pubitemid 16025343)
23. Giannotti B. Current treatment guidelines for topical corticosteroids. Drugs. 1988;36 Supp 5:9-14. (Pubitemid 19175854)
24. Bond CA. Dermatotherapy. In: Young LY, Koda-Kimble M (eds). Applied Therapeutics: The Clinical Use of Drugs. 6th Edition. Vancouver, Washington; Applied Therapeutics. 1995:36.1-36.5.
25. Scheuer E, Warshaw E. Allergy to corticosteroids: Update and review of epidemiology, clinical characteristics, and structural crossreactivity. Am J Contact Dermat. 2003;14(4):179-187. (Pubitemid 38072913)
26. Dooms-Goossens A, Morren M. Results of routine patch testing with corticosteroid series in 2073 patients. Contact Dermatitis. 1992;26(3):182-191.
27. Bircher AJ, Thurlimann W, Hunziker T, et al. Contact hypersensitivity to corticosteroids in routine patch test patients. A multi-centre study of the Swiss Contact Dermatitis Research Group. Dermatology. 1995;191(2):109-114.
28. Lutz ME, el-Azhary RA. Allergic contact dermatitis due to topical application of corticosteroids: Review and clinical implications. Mayo Clin Proc. 1997;72(12):1141-1144.
29. Isaksson M, Andersen KE, Brandao FM, et al. Patch testing with corticosteroid mixes in Europe. A multicentre study of the EE-CDRG. Contact Dermatitis. 2000;42(1):27-35. (Pubitemid 30052804)
30. Thomson KF, Wilkinson SM, Powell S, Beck MH. The prevalence of corticosteroid allergy in two U.K. centres: Prescribing implications. Br J Dermatol. 1999;141(5):863-866.
31. Marléne I, Magnus B. Contact allergen of the year: Corticosteroids. Dermatitis. 2005;16:3-5.
32. Lauerma AI, Reitamo S. Contact allergy to corticosteroids. J Am Acad Dermatol. 1993;28(4):618-622. (Pubitemid 23104239)
33. Seukeran DC, Wilkinson SM, Beck MH. Patch testing to detect corticosteroid allergy: is it adequate? Contact Dermatitis. 1997;36(3):127-130. (Pubitemid 27187245)
34. Dahl MGC. Hazards of topical steroid therapy. Adverse Drug Reaction Bull. 1985;115:428-431. (Pubitemid 16197606)
35. Nielson NV, Sorensen PN. Glaucoma induced by application of corticosteroids to the periorbital region. Arch Dermatol. 1978;114(6):953-954. (Pubitemid 9202413)
36. Epstein NM, Epstein WL, Epstein JH. Atrophic striae 36. in patients with inguinal intertrigo. Arch Dermatol. 1963;87:450.
37. Ammar NM, Rao B, Schwartz RA, Janniger CK. Adolescent striae. Cutis. 2000;65(2):69-70.
38. Nigam PK. Striae cutis distensae. Int J Dermatol. 1989;28(7):426-428.
39. Hettmannsperger U, Tenorio S, Orfanos CE, et al. Corticosteroids induce proliferation but do not influence TNF- or IL-1 beta-induced ICAM-1 expression of human dermal microvascular endothelial cells in vitro. Arch Dermatol Res. 1993;285(6):347-351. (Pubitemid 23265516)
40. Rapaport MJ, Rapaport V. Eyelid dermatitis to red face syndrome to cure: Clinical experience in 100 cases. J Am Acad Dermatol. 1999;41(3 Pt 1):435-442. (Pubitemid 29418512)
41. Plewig G, Kligman AM. Induction of acne by topical steroids. Arch Dermatol Forsch. 1973;247(1):29-52.
42. Fulton JE, Kligman AM. Aggravation of acne vulgaris by topical application of corticosteroids under occlusion. Cutis. 1968;4:1106.
43. Kaidbey KH, Kligman AM. The pathogenesis of topical steroid acne. J Invest Dermatol. 1974;62(1):31-36.
44. Litt JZ. Steroid-induced rosacea. Am Fam Physician. 1993; 48(1):67-71.
45. Mehan R, Ayers S. Perioral dermatitis. Arch Dermatol. 1964;89:803.
46. Takeda K, Arase S, Takahashi S. Side effects of topical corticosteroids and their prevention. Drugs. 1988;36 Suppl 5:15-23. (Pubitemid 19175855)
47. Friedman SJ, Butler DF, Pittelkow MR. Perilesional linear atrophy and hypopigmentation after intralesional corticosteroid therapy. Report of two cases and review of the literature. J Am Acad Dermatol. 1988;19(3):537-541.
48. Colomb D. Stellate spontaneous pseudoscars. Senile and presenile forms: Especially those forms caused by prolonged corticoid therapy. Arch Dermatol. 1972;105(4):551-554.
49. Lee NP, Arriola ER. Topical corticosteroids: Back to basics. West J Med. 1999;171(5-6):351-353.
50. Katz HI. Topical corticosteroids. Dermatol Clin. 1995;13(4):805-815.
51. Giannotti B, Pimpinelli N. Topical corticosteroids: Which drug and when? Drugs. 1992;44(1):65-71.
52. du Vivier A. Tachyphylaxis to topically applied steroids. Arch Dermatol. 1976;112(9):1245-1248.
53. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1-15.
54. Keipert JA, Kelly R. Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate. Med J Aust. 1971;1(10):542-544.
55. Gilbertson EO, Spellman MC, Piacquadio DJ, Mulford MI. Super potent topical corticosteroid use associated with adrenal suppression: Clinical considerations. J Am Acad Dermatol. 1998;38(2 Pt 2):318-321. (Pubitemid 28115240)
56. Ohman EM, Rogers S, Meenan FO. McKenna TJ. Adrenal suppression following low-dose topical clobetasol propionate. J R Soc Med. 1987;80(7):422-424. (Pubitemid 17118202)
57. Munro DD. The effect of percutaneously absorbed steroids on hypothalamic-pituitary-adrenal function after intensive use in inpatients. Br J Dermatol. 1976;94 Suppl 12:67-76.
58. Gomez EC, Frost P. Induction of glycosuria and hyperglycemia by topical corticosteroid therapy. Arch Dermatol. 1976;112(11):1559-1562.
59. Kubo T, Kojima A, Yamazoe S, et al. Osteonecrosis of the femoral head that developed after long-term topical steroid application. J Orthop Sci. 2001;6(1):92-94. (Pubitemid 32172490)
60. Wolkerstorfer A, Visser RL, De Waard van der Spek FB, et al. Efficacy and safety of wet-wrap dressings in children with severe atopic dermatitis: Influence of corticosteroid dilution. Br J Dermatol. 2000;143(5):999-1004.
61. http://www.clobex.com/CLOBEX-Ltn.pdf, Accessed Oct 17, 2008.
62. http://www.clobex.com/CLOBEX-SPRAY.pdf, Accessed Oct 17, 2008.
63. http://www.clobex.com/PCLOBEX-SHAMPOO.pdf, Accessed Oct 17, 2008.
64. http://www.fougera.com/products/documents/1077.PI.pdf. Accessed Oct 17, 2008.
65. http://www.fda.gov/medwatch/SAFETY/2003/03APR-PI/Temovate-Scalp-PI.pdf. Accessed Oct 17, 2008.
66. http://www.fda.gov/ohrms/dockets/dockets/06p0387/06P-0387-EC1-Attach-1. pdf. Accessed Oct 17, 2008.
67. http://www.fda.gov/ohrms/dockets/dockets/06p0387/06P-0387-EC1-Attach-2. pdf. Accessed Oct 17, 2008.
68. http://www.olux.com/pdfs/PI.PDF. Accessed Oct 17, 2008.
69. http://www.olux-e.com/pdfs/Olux-EPI.pdf. Accessed Oct 17, 2008.
70. http://www.fda.gov/medwatch/safety/2006/Aug-PIs/DiproleneOintment-PI.pdf. Accessed Oct 17, 2008.
71. http://www.spfiles.com/pidiprolenelot.pdf. Accessed Oct 17, 2008.
72. http://www.theodora.com/drugs/diprolene-gel-005-schering.html. Accessed Oct 17, 2008.
73. http://www.fougera.com/products/documents/1223.PI.pdf. Accessed Oct 17, 2008.
74. http://www.fougera.com/products/documents/1222.PI.pdf. Accessed Oct 17, 2008.
75. http://www.medicis.com/products/pi/pi-vanos.pdf. Accessed Oct 17, 2008.
76. http://www.dermik.com/docs/pdf/psorcon-ointment-PI.pdf. Accessed Oct 17, 2008.
77. http://www.aquapharma.com/pdf/CordranTapeJul06.pdf. Accessed Oct 17, 2008.
78. http://www.fda.gov/cder/pediatric/labels/BetameAF.pdf. Accessed Oct 17, 2008.
79. http://www.fda.gov/Cder/foi/label/2001/17691s19lbl.pdf. Accessed Oct 17, 2008.
80. http://www.fougera.com/products/documents/1008.PI.pdf. Accessed Oct 17, 2008.
81. http://products.sanofi-aventis.us/psorcon-e/psorcone.html. Accessed Oct 17, 2008.
82. http://www.fda.gov/cder/foi/label/2003/17994slr022-psorcon-lbl.pdf. Accessed Oct 17, 2008.
83. https://www.pharmaderm.com/pharmaderm/prescribing-info/apexicon-pi-cream. pdf. Accessed Oct 17, 2008.
84. http://www.fda.gov/medwAtch/SAFETY/2004/sep-PI/Halog-Oint-PI.pdf. Accessed Oct 17, 2008.
85. http://www.fda.gov/medwAtch/SAFETY/2004/sep-PI/Halog-PI.pdf. Accessed Oct 17, 2008.
86. http://www.fda.gov/medwatch/SAFETY/2004/sep-PI/Halog-Solution-PI.pdf. Accessed Oct 17, 2008.
87. http://www.fda.gov/Medwatch/SAFETY/2004/sep-PI/Halog-E-Cream-PI.pdf. Accessed Oct 17, 2008.
88. http://www.fougera.com/products/documents/1032.PI.pdf. Accessed Oct 17, 2008.
89. http://www.fougera.com/products/documents/1027.PI.pdf. Accessed Oct 17, 2008.
90. http://www.fougera.com/products/documents/1030.PI.pdf. Accessed Oct 17, 2008.
91. http://www.fougera.com/products/documents/1035.PI.pdf. Accessed Oct 17, 2008.
92. http://www.topicort.com/uploadFiles/topicort-PI.pdf. Accessed Oct 17, 2008.
93. http://www.fda.gov/CDER/foi/label/2002/18498s8lbl.pdf. Accessed Oct 17, 2008.
94. http://nccs-dailymed-2.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id= 1866&type=display. Accessed Oct 17, 2008.
95. http://nccs-dailymed-2.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id= 5097&type=display. Accessed Oct 17, 2008.
96. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=2984. Accessed Oct 17, 2008.
97. http://www.fda.gov/cder/foi/label/2001/17536s24lbl.pdf. Accessed Oct 17, 2008.
98. http://www.luxiq.com/WebPages/LuxiqPI.pdf. Accessed Oct 17, 2008.
99. http://www.fougera.com/products/documents/1069.PI.pdf. Accessed Oct 17, 2008.
100. http://www.dermik.com/docs/pdf/psorcon-cream-PI.pdf. Accessed Oct 17, 2008.
101. http://www.fougera.com/products/documents/1005.PI.pdf. Accessed Oct 17, 2008.
102. http://www.pfizer.com/files/products/uspi-florone.pdf. Accessed Oct 17, 2008.
103. http://www.fda.gov/Cder/foi/label/2002/19543s11s13lbl.pdf. Accessed Oct 17, 2008.
104. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1866. Accessed Oct 17, 2008.
105. http://www.fougera.com/products/documents/1150.PI.pdf. Accessed Oct 17, 2008.
106. http://74.125.113.104/search?q=cache:6JxA0eDYKZsJ:dailymed.nlm.nih.gov/ dailymed/drugInfo.cfm%3Fid%3D5199+cordran+ointment&hl=en&ct=clnk&cd= 1&gl=us. Accessed Oct 17, 2008.
107. http://www.fda.gov/cder/foi/label/2002/19625s12s13lbl.pdf. Accessed Oct 17, 2008.
108. http://www.fda.gov/CDER/foi/label/2002/19796s8s15lbl.pdf. Accessed Oct 17, 2008.
109. http://www.perrigo.com/uploadedFiles/Rx/products/M/5D800RCJ1.pdf. Accessed Oct 17, 2008.
110. http://www.perrigo.com/uploadedFiles/Rx/products/T/TriamcinolonePI- Master.pdf. Accessed Oct 17, 2008.
111. http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=1860&type= display. Accessed Oct 17, 2008.
112. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1246. Accessed Oct 17, 2008.
113. http://www.fda.gov/cder/foi/label/2002/18726s9s12lbl.pdf. Accessed Oct 17, 2008.
114. http://www.fda.gov/medwAtch/SAFETY/2004/apr-PI/Topicort-PI-Cream.pdf. Accessed Oct 17, 2008.
115. http://www.healthpoint.com/divisions/derm/PI/ClodermCreamPI.pdf. Accessed Oct 17, 2008.
116. https://www.pharmaderm.com/pharmaderm/prescribing-info/pandel-pi-cream. pdf. Accessed Oct 17, 2008.
117. http://www.capexshampoo.com/shampoo/product-insert.cfm. Accessed Oct 17, 2008.
118. http://pi.watson.com/data-stream.asp?product-group=1221&p= pi&language=E Accessed Oct 17, 2008.
119. http://www.fougera.com/products/documents/1216.PI.pdf. Accessed Oct 17, 2008.
120. https://www.pharmaderm.com/pharmaderm/prescribing-info/ cutivate-lotion-pi.pdf. Accessed Oct 17, 2008.
121. http://products.sanofi-aventis.us/dermatop/dermatop.html. Accessed Oct 17, 2008.
122. http://products.sanofi-aventis.us/dermatop-ointment/dermatop-oint.html. Accessed Oct 17, 2008.
123. http://www.fougera.com/products/documents/1172.PI.pdf. Accessed Oct 17, 2008.
124. http://www.desonate.com/forms/Desonate-Prescription-Info.pdf. Accessed Oct 17, 2008.
125. http://www.tarousa.com/media/oMedia/HydroBUT-cream.pdf. Accessed Oct 17, 2008.
126. http://www.taro.com/media/oMedia/HydroInsert.PDF. Accessed Oct 17, 2008.
127. http://www.triaxpharma.com/pdfs/LocoidLipocreamPI.pdf. Accessed Oct 17, 2008.
128. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1388. Accessed Oct 17, 2008.
129. http://www.fda.gov/Cder/foi/label/2003/17950slr021-westcort-lbl.pdf. Accessed Oct 17, 2008.
130. http://www.fda.gov/ohrms/dockets/AC/03/briefing/3999B1-07- Diprosone%20Lotion%20Label.pdf. Accessed Oct 17, 2008.
131. https://www.pharmaderm.com/pharmaderm/prescribing-info/aclovate-pi.pdf. Accessed Oct 17, 2008.
132. http://www.verdeso.com/verdeso/pi.php. Accessed Oct 17, 2008.
133. http://www.perrigo.com/uploadedFiles/Rx/products/D/45802-422.pdf. Accessed Oct 17, 2008.
134. https://www.pharmaderm.com/pharmaderm/prescribing-info/lokara-pi-lotion. pdf. Accessed Oct 17, 2008.
135. http://www.fougera.com/products/documents/1170.PI.pdf. Accessed Oct 17, 2008.
136. http://www.fougera.com/products/documents/1020.PI.pdf. Accessed Oct 17, 2008.
137. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1637. Accessed Oct 17, 2008.
138. http://www.hillderm.com/prescribing-information/derma-smootheso.shtml. Accessed Oct 17, 2008.
139. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=1441. Accessed Oct 17, 2008.
140. http://www.perrigo.com/uploadedFiles/Rx/products/H/2707-insert.pdf. Accessed Oct 17, 2008.
141. http://www.perrigo.com/uploadedFiles/Rx/products/H/45802-014-004.pdf. Accessed Oct 17, 2008.
142. http://www.fougera.com/products/documents/1092.PI.pdf. Accessed Oct 17, 2008.
143. http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=6238. Accessed Oct 17, 2008.
144. http://www.jsjpharm.com/pi/texacort-pi.pdf. Accessed Oct 17, 2008.
145. Shroot B, Pillai R. Potency and side effects of halogenated corticosteroids revisited. J Am Acad Dermatol. 2005;52:40.
146. du Vivier A, Stoughton RB. Tachyphylaxis to the action of topically applied corticosteroids. Arch Dermatol. 1975;111(5):581-558.
147. Miller JJ, Roling D, Margolis D, Guzzo C. Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis. J Am Acad Dermatol. 1999;41(4):546-549. (Pubitemid 29480401)
148. Katz HI, Prawer SE, Medansky RS, et al. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991;183(4):269-274.